

Is Your BODs Bored of just your Compliance Dashboards?

Thomas Costa, JD, Member, US Board of Directors, Sanofi; Former Vice President, US Compliance and Ethics, Bristol-Myers Squibb, Washington, DC

Sarah A. Franklin, JD, Partner, Covington & Burling LLP; Former Attorney, Federal Trade Commission, Washington, DC

Jennifer McGee, JD, Vice President and Chief Compliance Officer, Otsuka America Pharmaceutical, Inc., Rockville, MD

Brian Van Hoy, Vice President, G&M Health LLC; Former Director, Ethics and Compliance, Eli Lilly, Bridgewater, NJ (Moderator)

Is your BODs Bored of your Compliance Dashboards?

Scope

- This mini summit session will discuss the important role BODs provide for an effective compliance program. Listen to experienced compliance and board members discuss how compliance must be incorporated into BOD meeting agendas, how to be effective with limited time, how to educate BOD members on the importance of compliance and other compliance related topics.

Is your BODs Bored of just your Compliance Dashboards?

Key Take-Aways

- Discuss reporting structure with CEO and GC – BOD Access
- Educate BOD on government expectations of Board Members
- Questions – Demonstrate the importance of BOD Members asking questions
- Provide regular training on compliance topics to Board Members
- Provide regular enforcement updates within the industry
- Provide summary of compliance related activities – seven elements overview